Authors' Reply: Joint Interpretation of Long-Chain and Very Long–Chain Sphingolipid Associations with Mortality in Hemodialysis
Journal of the American Society of Nephrology · 2026-11 · 37 (11) · 2582-2583
DOI: 10.1681/asn.0000001212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 21.08.2026. Verfasst von Benjamin Lidgard und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Washington, Seattle, Washington. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of Washington, Seattle, Washington.
ORCID-Profile: Benjamin Lidgard, Colleen M Sitlani, Rozenn N Lemaitre
Förderung
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
Zitieren
APA
Lidgard, B., Jensen, P. N., Sitlani, C. M., & Lemaitre, R. N. (2026). Authors' Reply: Joint Interpretation of Long-Chain and Very Long–Chain Sphingolipid Associations with Mortality in Hemodialysis. Journal of the American Society of Nephrology, 37(11), 2582-2583. https://doi.org/10.1681/asn.0000001212
Vancouver
Lidgard B, Jensen PN, Sitlani CM, Lemaitre RN. Authors' Reply: Joint Interpretation of Long-Chain and Very Long–Chain Sphingolipid Associations with Mortality in Hemodialysis. Journal of the American Society of Nephrology. 2026;37(11):2582-2583. doi:10.1681/asn.0000001212
BibTeX
@article{Lidgard2026,
author = {Lidgard, Benjamin and Jensen, Paul N and Sitlani, Colleen M and Lemaitre, Rozenn N},
title = {Authors' Reply: Joint Interpretation of Long-Chain and Very Long–Chain Sphingolipid Associations with Mortality in Hemodialysis},
journal = {Journal of the American Society of Nephrology},
year = {2026},
volume = {37},
number = {11},
pages = {2582--2583},
doi = {10.1681/asn.0000001212}
}
EUVIMED